drugset / Trial / NCT04791514
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
NaSequentialOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
Timeline
- Start
- 2022-03-29
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
Outcome
Outcome not reported
Stopped: “Low enrolment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil Palmitil | Small molecule | 320 ug | Inhaled |